A development program for BCV as a treatment for viral hemorrhagic cystitis (vHC) and HHV-6 encephalitis following hematopoietic stem cell or kidney transplantation, with the goal of filing for EU approval after a Phase 3 trial and commercializing the product across regions including Europe, the United States and China.